With Q1 2026 earnings season kicking off in mid-April, Wall Street's consensus estimates paint a picture of modest 6.2% year-over-year earnings growth for the S&P 500. But beneath the headline number, three sectors show signs of significantly beating expectations.
1. Healthcare: The GLP-1 Ripple Effect
The GLP-1 drug revolution — led by Novo Nordisk's semaglutide and Eli Lilly's tirzepatide — continues to reshape not just pharmaceutical revenues but the entire healthcare value chain. What's underappreciated is the secondary effect: as obesity-related comorbidities decline, health insurers are beginning to see lower claims in cardiovascular and diabetes management.
UnitedHealth Group's medical cost ratio has quietly improved by 80 basis points over the past two quarters, a trend that analysts have been slow to extrapolate. Meanwhile, contract research organizations (CROs) like IQVIA and Charles River Laboratories are benefiting from a surge in clinical trials as every major pharma company races to develop GLP-1 competitors.
Consensus EPS growth estimate: 8.3% | Our assessment: 11-13% likely
2. Industrials: Infrastructure Spending Hits Stride
The Infrastructure Investment and Jobs Act, the CHIPS Act, and the Inflation Reduction Act collectively represent over $2 trillion in committed federal spending. But the money has taken years to flow from authorization to actual construction contracts. That inflection point is now.
According to the Census Bureau, construction spending on manufacturing facilities hit $236 billion annualized in January 2026 — triple the 2020 level. Companies like Caterpillar, Eaton, and Parker Hannifin are seeing order books extend to 18+ months.
The key metric to watch: Industrial production capacity utilization, currently at 79.4%, is approaching the 80%+ level that historically triggers pricing power and margin expansion.
Consensus EPS growth estimate: 5.1% | Our assessment: 8-10% likely
3. Financials: Net Interest Income Stabilizes
The banking sector has been caught between two narratives: higher rates are good for net interest margin (NIM), but higher rates also reduce loan demand and increase credit losses. The stabilization of rates at 4.25%-4.50% is resolving this tension favorably.
Regional banks, which were battered in the 2023 crisis, are showing particular strength. Deposit costs have plateaued (average cost of interest-bearing deposits at 2.85%), while commercial loan yields continue to reprice higher on renewal. The result: NIM expansion of 5-15 basis points across the regional banking sector.
Credit quality remains the wild card, but net charge-offs are running at 0.65% — elevated versus 2022's 0.32% but well below recessionary levels and in line with the pre-pandemic 10-year average of 0.58%.
Consensus EPS growth estimate: 4.7% | Our assessment: 7-9% likely
What This Means for Investors
Earnings surprises drive short-term stock price reactions, but more importantly, they signal durable trends. All three sectors we've identified benefit from structural tailwinds (healthcare innovation, infrastructure spending, rate stabilization) rather than one-time factors.
Key Takeaways
- Q1 earnings season may deliver broader upside than the 6.2% consensus suggests
- Healthcare's GLP-1 halo effect extends to insurers and CROs, not just drug manufacturers
- Infrastructure spending is transitioning from legislation to actual contract revenue
- Regional banks offer a compelling value opportunity as NIM expansion accelerates
- Watch for management commentary on tariff impacts and supply chain adjustments
